Highlights

  • Paragon Care shares jumped 10% to AUD 0.16 after disclosing an expected distribution of AUD $11.7 million to $15.8 million from the Infinity Retail Pharmacy Group administration — a recovery against receivables that were fully provisioned in 1H FY26, meaning any amount received flows directly to the Earnings line.
  • The company has already banked a AUD $3.4 million cash recovery from the ATO relating to GST previously paid on the Infinity Group receivable, providing immediate and concrete Balance Sheet benefit independent of the administration outcome.
  • FY26 Revenue is forecast at approximately AUD $3.7 billion, with underlying EBITDA expected in the range of AUD $95 million to $100 million, incorporating the April 1 Acquisition of Haju — subject to year-end audit finalisation.

 

Paragon Care Limited (ASX:PGC), one of Australia's largest providers of medical equipment, devices, consumables, and pharmaceuticals to healthcare markets across Australia, New Zealand, and Asia, delivered a trading update on June 1, 2026, that combined two distinct positive signals: a material earnings forecast for FY26 and an unexpected potential recovery from the Infinity Retail Pharmacy Group's administration proceedings. Shares responded with a 10% gain to AUD 0.16, making Paragon Care one of the more pronounced movers on the ASX on the day.

The market's reaction is explained by the accounting mechanics of the situation. When Paragon Care recognised a 100% provision against its Infinity Group receivables in its 1H FY26 results following the administrator and receiver appointments in December 2025, the full exposure was effectively removed from earnings expectations. Any recovery from the administration process therefore represents pure upside relative to the provisioned position — a Reversal of a prior-period Impairment charge that flows directly and positively through the income statement in the period it is recognised.

The Infinity Group: From Exposure to Recovery

The Infinity Retail Pharmacy Group was a significant customer of Paragon Care, generating trading receivables that became irrecoverable following the appointment of receivers and administrators in December 2025. Pharmacy group collapses of meaningful scale are relatively uncommon in the Australian healthcare Supply chain, and the Infinity administration created a notable bad Debt exposure for Paragon Care that weighed on investor sentiment through the first half of FY26. The decision to provision 100% of the exposure at 1H FY26 results was a conservative but appropriate accounting response to the uncertainty of the administration outcome.

The June 1 update discloses that the administrators have prepared a preliminary Estimated Outcome Analysis indicating Paragon Care would receive a distribution in the range of approximately AUD $11.7 million to $15.8 million. This represents a Recovery Rate of approximately 24% to 32.5% of the company's total outstanding exposure to the Infinity Group. While the Estimated Outcome Analysis is described as preliminary and indicative — requiring feedback from all secured lenders before finalisation — even the low end of this range represents a material positive revision to the earnings outlook that had effectively assumed zero recovery.

The ATO GST Recovery: Immediate, Concrete, and Already Banked

Separate from and additional to the administration recovery, Paragon Care has already received a cash payment of AUD $3.4 million from the Australian Taxation Office relating to GST previously paid on the Infinity Group receivable. This recovery mechanism — available to suppliers who have remitted GST on invoices that subsequently become Bad Debts — is straightforward but often overlooked in investor analysis of bad debt scenarios. The ATO payment represents a concrete, already-realised cash recovery that reduces the effective net cost of the Infinity Group exposure, independent of the uncertain and still-evolving administration distribution process.

The combination of the $3.4 million ATO recovery already banked and the prospective $11.7 million to $15.8 million from the administration process means the total potential recovery from the Infinity Group exposure could reach AUD $15.1 million to $19.2 million. Against a fully provisioned receivable, this entire range represents earnings that were not in any consensus or management forecast entering the second half of FY26.

Personal Guarantee Optionality: Additional Recovery Not Yet Quantified

A further dimension of the recovery narrative is the existence of personal guarantees that Paragon Care has obtained from the owners and directors of the Infinity Group. The June 1 disclosure notes that the AUD $11.7 million to $15.8 million distribution estimate is prior to enforcing these guarantees — meaning there is a potential additional recovery channel that has not yet been factored into the preliminary administrator analysis. The enforceability and quantum of personal guarantee recoveries in administration contexts is inherently uncertain and can be protracted, but the existence of documented guarantees provides legal standing for Paragon Care to pursue recovery beyond the administration distribution.

For investors modelling the upside scenario, the guarantee recovery represents a potential incremental positive that could become relevant in FY27 or beyond, depending on the pace and outcome of legal enforcement proceedings. It is not included in the preliminary Estimated Outcome Analysis and should not be incorporated into near-term earnings models, but it does materially improve the risk profile of the total Infinity Group exposure relative to a scenario where the administration distribution is the sole recovery channel.

FY26 Revenue and EBITDA: A Business Performing at Scale

Alongside the Infinity Group recovery narrative, Paragon Care's FY26 earnings update contains substantive information about the underlying performance of the core business. Revenue is forecast at approximately AUD $3.7 billion — a figure that positions Paragon Care among the largest healthcare distribution businesses listed on the ASX by revenue. This revenue base reflects both organic growth and the contribution of acquisitions, most recently the Haju acquisition completed on April 1, 2026.

Underlying EBITDA is forecast in the range of AUD $95 million to $100 million, inclusive of the Haju contribution and subject to year-end audit finalisation. At the midpoint of AUD $97.5 million, this implies an underlying EBITDA Margin of approximately 2.6% on the $3.7 billion revenue forecast. This margin profile is characteristic of healthcare distribution businesses, where the Value Added by the distributor — logistics, compliance, inventory management, supplier aggregation — is real but the gross margin is structurally compressed by the high-Volume, low-margin Economics of pharmaceutical and consumables distribution. Net debt is expected to be in the range of 2.0 to 2.5 times EBITDA, assuming full-year contribution from acquisitions.

The Haju Acquisition: Adding Scale in April

The completion of the Haju acquisition on April 1, 2026 represents the most recent addition to Paragon Care's business consolidation strategy. The company has pursued an acquisition-led growth approach, aggregating complementary healthcare distribution, consumables, and pharmaceutical businesses to build scale and broaden its product and customer coverage across Australian, New Zealand, and Asian healthcare markets. The inclusion of Haju in the FY26 revenue and EBITDA forecasts means the disclosed numbers incorporate only three months of Haju contribution in FY26 — a partial-year effect that limits the visible FY26 earnings impact but provides a full-year contribution from FY27 onwards.

Cost Headwinds: Logistics and Oil-Linked Pricing Pressure

The FY26 update does not present an entirely positive operational picture. Management acknowledged that logistics costs have been challenging during the period, a reflection of geopolitical disruptions to global shipping routes and the ongoing complexity of supply chain management across a multi-geography healthcare distribution business. Additionally, pricing pressures from manufacturers — some of whom have been compelled to increase product prices due to elevated oil prices affecting input and transportation costs — have created a margin headwind that the company has been managing through disciplined cost management and Working Capital optimisation.

These pressures are not unique to Paragon Care: logistics cost Inflation and oil-linked manufacturer price increases have affected healthcare distribution businesses across multiple geographies. However, they do constrain the pace of margin improvement at a time when the company is absorbing acquisition integration costs and building toward a scale that should eventually generate procurement and operational Leverage. The stable underlying trading performance noted by management suggests the business is holding its position commercially despite these headwinds, rather than losing ground to competitors.

Balance Sheet and Leverage Considerations

The net debt guidance of 2.0 to 2.5 times EBITDA on a full-year acquisition contribution basis represents a leverage profile that is meaningful but not atypical for a healthcare distribution business of Paragon Care's scale and acquisition activity level. At the midpoint EBITDA estimate of AUD $97.5 million, this implies net debt in the range of approximately $195 million to $244 million. The Infinity Group recovery, when recognised, will provide a positive contribution to net debt reduction — the ATO's $3.4 million has already been received in cash, and any administration distribution will similarly reduce net debt when settled.

Conclusion

The 10% share price surge in Paragon Care on June 1, 2026, is a response to two distinct but reinforcing positive signals: the emergence of a material recovery from a receivable exposure that the market had effectively written to zero, and confirmation of a FY26 revenue and EBITDA trajectory that demonstrates the core business is performing at scale. The AUD $3.4 million ATO refund already received, the preliminary AUD $11.7 million to $15.8 million administration distribution estimate, and the potential upside from personal guarantee enforcement together create an earnings recovery narrative that will play out across FY26 and FY27. Set against a backdrop of acknowledged logistics and cost headwinds, the update presents a company navigating real operational challenges while delivering positive earnings surprises from an unexpected recovery source.